Sign in
Taking peoplePhase 3

Sulodexide to prevent repeat blood clots in older adults

Tests sulodexide against placebo for preventing repeat venous thromboembolism in older people.

Key facts

Who runs it
Arianna Anticoagulazione Foundation
Where
Italy29 sites in 1 countryChoose a country to see its sites
Registry title
Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study)
Status
Recruiting
Phase
Phase 3
People taking part
1,455 people, planned
Started
21 Dec 2020
Expected to end
2 Jan 2027
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Sulodexide
  • Sulodexide and placebo
  • Placebo
Record updated
31 July 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 75 or older after a first blood clot in the deep veins of the upper leg, or in the lungs, who have at least one bleeding risk factor. It tests Sulodexide against placebo for 12 months to prevent a new clot.

Age
75 years or older
Sex
All sexes
Disease stage
A first clot in the deep veins of the upper leg (proximal DVT) and/or a lung clot (PE). It had no clear cause, or only weak or removed causes. People must have at least one bleeding risk factor, such as high blood pressure, kidney or liver failure, low platelets, diabetes, anemia, past stroke, frequent falls (>2 /years), alcohol abuse, poorly controlled blood thinners, or use of NSAIDs or antiplatelet drugs (ASA maximum 140 mg/die).
Earlier treatment
People must have had blood thinner treatment (any drug) for at least 3 months. It must not have been stopped for more than 30 days. They must have no other reason to take blood thinners.

Main reasons for not taking part

  • The clot came after surgery or major injury within 3 months, bed rest over 4 days, or a cast or immobility within 3 months
  • Severe, life-threatening lung clot, or one treated with clot-dissolving drugs
  • A clot only in the lower leg veins or in surface veins, or a clot in other places
  • Blood thinners for less than 3 months, or stopped for over 30 days
  • More than one past clot episode

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Patients with a first event of proximal lower extremity DVT and / or PE, idiopathic or associated with weak or removed risk factors
  • Patients aged ≥75 years at the time of enrolment
  • Patients with at least one of the known risk factors of bleeding (APPENDIX 1):; Hypertension; Renal failure; Thrombocytopenia; Diabetes; Antiplatelet therapy (ASA maximum 140 mg/die); Frequent falls (>2 /years); Nonsteroidal anti-inflammatory drug; Liver failure; Previous Stroke; Anemia; Poor anticoagulant control; Alcohol abuse
  • Patients of both sexes
  • Patients who at the time of enrolment have already undergone a period of anticoagulant therapy (AT, with any medication) of at least 3 months and the therapy has not been suspended for more than 30 days
  • Patients with no other AT indications
  • Patients capable and able to provide informed consent

Who cannot take part

  • "Provoked" index event, which occurred:; Within 3 months of surgery or major trauma,; Bed Rest > 4 days,; Cast / immobility within 3 months
  • Index event represented by severe PE, with life threatening risk or treated with thrombolytic therapy
  • Anticoagulant therapy for less than 3 months at the time of enrolment
  • Discontinuation of anticoagulant therapy for over thirty days at the time of enrolment
  • Index event represented by isolated distal DVT or superficial venous thrombosis
  • Patients aged <75 years at the time of the recruitment visit
  • Thrombotic event in sites other than the deep proximal veins of the lower limbs
  • Recurrent episodes of DVT ± PE

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The study aims at optimizing extended management of elderly patients (> 75 years) with at least one of the known bleeding risk factor, who suffered from first episode of venous thromboembolism of the lower extremity (proximal deep vein thrombosis with or without pulmonary embolism) (VTE). Patients were randomized to receive three different treatment: Sulodexide 250 mg BIS in die; Sulodexide 500 BID in die or indistinguishable placebo to verify the efficacy and safety of extended treatment for 12 months with Sulodexide (Vessel®) in the secondary prevention of Deep Vein Thrombosis / Pulmonary Embolism (DVT/PE) recurrence.

The 3 groups in the trial

  • Treatment AExisting treatment, for comparison

    Sulodexide (Vessel) 2 capsules of 250 LSU BID, for 12 months

    Treatment: Sulodexide

  • Treatment BExisting treatment, for comparison

    Sulodexide (Vessel) 1 capsule of 250 LSU and 1 indistinguishable placebo capsule BID., for 12 months

    Treatment: Sulodexide and placebo and Placebo

  • Treatment CPlacebo, for comparison

    2 indistinguishable placebo capsules BID, for 12 months

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Sulodexide (VESSEL®) for the Prevention of Recurrent Venous Thromboembolism in Elderly Patients After a First Episode of Venous Thrombembolism
Plain-language title
Sulodexide to prevent repeat blood clots in older adultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Publications
Record updated
31 July 2024